Related Experiment Videos
[Cerebral and spinal angiography with metrizamide (amipaque) (author's transl)]
Rofo : Fortschritte Auf Dem Gebiete Der Rontgenstrahlen Und Der Nuklearmedizin
|November 1, 1978
Abstract:
Metrizamide (Amipaque) has been used as the contrast medium for angiography in neuroradiological investigations. Solutions containing 280 mgI/ml. are well tolerated and produce good contrast. The most important difference from previously used contrast media is the lack of pain when injections are made selectively or super-selectively into the external carotid artery and its branches, or into the spinal arteries.
Insights
Metrizamide (Amipaque) offers well-tolerated, high-contrast angiography in neuroradiology. This contrast medium significantly reduces injection pain in selective external carotid artery and spinal artery procedures.
Area of Science:
- Neuroradiology
- Medical Imaging
- Pharmacology
Background:
- Traditional contrast media for neuroradiological angiography often cause significant patient discomfort.
- Developing safer and more effective contrast agents is crucial for improving diagnostic procedures.
Purpose of the Study:
- To evaluate the efficacy and tolerability of Metrizamide (Amipaque) as a contrast medium in neuroradiological investigations.
- To compare the pain experience associated with Metrizamide versus previously used contrast media.
Main Methods:
- Utilized Metrizamide solutions at a concentration of 280 mgI/ml for angiography.
- Administered the contrast medium selectively or super-selectively into the external carotid artery and its branches, and spinal arteries.
Main Results:
- Metrizamide solutions at 280 mgI/ml demonstrated good tolerability and produced excellent contrast.
- A key finding was the marked reduction in injection-related pain when using Metrizamide, particularly in selective and super-selective procedures.
Conclusions:
- Metrizamide (Amipaque) is a well-tolerated and effective contrast medium for neuroradiological angiography.
- The reduced pain profile of Metrizamide represents a significant advancement over older contrast agents for specific vascular territories.